Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab

J Peguero¹, E Felip², B Doger³, M Majem⁴, E Carcereny⁵, T Clay⁶, P Bajaj⁷, M G Krebs⁸, F Triebel⁹

- gy Consultants, Houston, Texas, USA Hebron Institute of Oncology, Barcelona, Spain ión Jimenez Díaz, Madrid, Spain Il de la Santa Creu i Sant Pau, Barcelona, Spain Català d'Oncologia Badalona-Hosoital Germa

- Spain 6-St John of God Subiaco Hospital, Perth, Australia 7-Tasman Health Care, Queensland, Australia 8-Division of Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and The Christe MHS Foundation Trust, Manchest 9- Research & Development, Immutep S.A.S., Orsay, France

Background



Eftilagimod alpha (efti; previously IMP321) is a soluble LAG-3 protein that binds to a subset of MHC class II molecules to mediate antigen presenting cell (APC) and then CD8 T-cell activation.

Efti is a first-in-class APC activator

The rationale to combine efti and nembrolizumab comes from their complementary mechanisms of action. Efti activates APCs and leads to an increase in activated T cells which effect potentially reduces the number of non-responders to pembrolizumab.

Combining an APC activator like efti to pembrolizumab is therefore fundamentally different from many other trials combining two checkpoint inhibitors like an anti-LAG-3 mAb with an anti-PD-1 mAb.

Previous clinical trial experience with the same combination used in metastatio patients (TACTI-mel study, melanoma IMP321-P012, NCT02676869) suggests that the combination is safe and shows encouraging signs of efficacy.

We hereby report initial results of stage 1 of a phase II trial (TACTI-002).

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from SITC® and the author of this poster



Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA provided pembrolizumab for the study. The trial-identifiers are IMP321-P015 (Sponsor code), Keynote-PN798 (MSD code), 2018-001994-25 (EudraCT) and NCT03625323 (ClinicalTrials.gov). Corresponding author: Frederic Triebel, frederic.triebel@immutep.com


Trial Design Part A: 1st line, PD-X naïve NSCLC; Part B: 2nd line, PD-X refractory NSCLC:

- Part C: 2nd line PD-X naive HNSCC
- Simon's optimal two-stage design Primary endpoint: objective response rate (ORR) as per iRECIST
- Secondary endpoints: progression free survival (PFS) and overall survival (OS) Blood samples for PK/PD assessments and anti-drug antibody evaluation are collected

During the first stage, the N1 patients are recruited. Additional patients (N2) will be recruited for each part if the pre-specified threshold for ORR is met. In total, 109 patients are planned to be enrolled.

Indication	Threshold r1	Initial No. of pts (N1)	Add. No. of pts (N2)	N total
Part A: NSCLC 1st line	4	17	19	36
Part B: NSCLC 2 nd line	1	23	13	36
Part C: HNSCC	2	18	19	37

Efti is administered as 30 mg subcutaneous injection every 2 weeks for the first 8 cycles and every 3 weeks for 9 following cycles. Pembrolizumab is administered at a standard dose of 200 mg intravenous infusion every 3 weeks for maximum 2 years.



Legend: 1 cycle = 3 weeks; q2w - every 2 weeks, q3w every 3 weeks

una and Cafatul Ex

Exposure a	nd Safe	ety⊥						
Summary - Exposure:				Safety Parameters			N of patients (%)	
In total 33 pts were enrolled until data			Pts with any TEAE			29 (87.9)		
cut-off ¹ . Part A (N=17) stage 1			Pts with any SAE			10 (30.3)		
enrollment was completed in June			thereof rel. to IMP321 / pembrolizumab			1 (3.0) / 1 (3.0)		
2019. Recruitment into part B + C stage 1 and into part A stage 2 is ongoing			pembrolizumab Pts with any grade ≥3 TEAE thereof rel. to IMP321 /			15 (45.5) 2 (6.1) / 2 (6.1)		
							Pts received median 7 (range 1-14) IMP321 injections and median of 5	
(range 1-10) per			ons		Overview -	Safety:		
Adverse events ≥ grade 3 and related to either pembrolizumab or efti				 1 fatal TEAE (Hemoptysis, grade 5) unrelated to both study treatments 				
Adverse event (PT)	Grade 3 N (%)	Grade 4 N (%)	Seri	• 1 patient with SAEs related to both study drugs (see table left)				
Atrial fibrillation	1(3)		Yes			ding to discontinu		
Hepatitis		1 (3)	Yes		 Hepatitis grade 4 – be discontinued 		oth study drugs	
Diarrhea	1 (3)	- No				Diarrhoea grade 3 – pembrolizumab discontinued		
Adverse events o	ccured in ≥	10 % of p	ts (N:	=33 ir	n total)			
Adverse event (PT)		Any Gr N (%			Grade 3 N (%)	Grade 4 N (%)	Grade 5 N (%)	
Asthenia		9 (27.3)			-		-	
Cough		12 (36.4)					-	
Decreased appetite		6 (18.2)						
Diarrhoea		5 (15.2)		1 (3.0) -				
Dyspnoea		6 (18	6 (18.2)		3 (9.1) -			
Fatigue		5 (15.2)			-	-	-	

1 - Data cut-off date: 9th Oct 2019

Nausea

APC...antigen-presenting cell AE...adverse event BOR...best overall response DCR...disease control rate DMC...Data Monitoring Committee ECGG...Eastern Cooperative Oncology Group HNSCC...head and neck squamous cell cancer ICI...immune checkpoint inhibitor IRECIST...Immune Response Evaluation Criteria In Solid Tumors

4 (12.1)

LAG-3...Lymphocyte Activation gene-3 MHC...Major Histocompatibility Complex NSCLC...non-small cell lung cancer PD-11, PD-12...Programmed Death ligand-1, -2 PD-X...PD-1 or PD-L1 targeted therapy PFS...progression-free survival ORR...objective response rate SAE...serious adverse event TEAE...treatment emergent adverse event

Non-small cell lung cancer stage pts with stage IIIB not amenable to curative treatment or stage IV not amenable to Fema Male EGFR/ALK based therapy who were treatment naïve for advanced/

Initial Efficacy Part A stage 1 - PD-X naive NSCLC²

- metastatic disease were enrolled Majority of pts male and had ECOG of 0 58 % of pts previously treated for
- NSCLC with surgery, radiochemo or radiotherapy
- Patients with different PD-I 1 status enrolled (< 1 %; 1-49 %; ≥ 50 %); data

Baseline Characteristics:


- not yet available for all pts 58 % ≥ 65 yrs

Tumor response - BOR as per iRECIST	N (%) Total (N=17)
Complete Response (iCR)	0 (0)
Partial Response (iPR)	7 (41.2)
Stable Disease (iSD)	6 (35.3)
Progressive Disease (iPD)	4 (23.5)
Objective Response Rate (ORR)	7 (41.2)
Disease Control Rate (DCR)	13 (76.5)

Summary – Results:

- All 17 patients enrolled to part A stage 1 were evaluable for efficacy Median time of FU was 5.6 months (0.7 - 7.4)
- At data cut-off 12 pts (71 %) were still under treatment thereof 9 pts (53 %) reached 24week landmark already \rightarrow median PFS not yet reached
- ORR (iRECIST) observed: 41.2 % → stage 2 allowed to be opened
- Target lesions decrease in pts with iPR as BOR was between 38 % and 64 % · None of the pts with response progressed

thus far




Conclusion

Combination of efti and pembrolizumab in PD-X naïve or refractory NSCLC. and in HNSCC patients is safe and well tolerated -> 2nd stage for part A opened by DMC

- ORR of 41.2 % in PD-L1 all comer in 1st line NSCLC → 12/17 (71%) still under treatment \rightarrow encouraging signs of clinical activity in a PD-L1 all comer trial (Pembrolizumab alone in 1-49 % PD-L1 ORR of 16.7 % in KN-042)
- Initial results are encouraging that combining the APC activator efti with the checkpoint inhibitor pembrolizumab may result in synergistic therapeutic activity

Recruitment of part B and C stage 1 and part A stage 2 are ongoing



immutep